ESMO Breast Cancer 2026
Trials whose public commentary places their results at ESMO Breast Cancer 2026, May 6–8, 2026. A trial is listed only when at least two public sources, from two publishers, place its results or presentation at the meeting; each row says how many did.
9 trials: 0 with reports and 9 with no report yet. Organised by European Society for Medical Oncology (ESMO); Erudio is not affiliated with it.
Focused$750Standard$1,250Deep$1,950Pricing
Reports: each is priced by its size, licensed permanently for your organization's internal use, with MCP access for your AI agent. Buy on the report's page. Team and enterprise access
What clinicians said about each trial in public, every statement linked to its source. Counts: verified statements, and how many of them come from speakers whose clinical role the NPI registry or their institution's staff page confirms.
No published report on a trial placed at ESMO Breast Cancer 2026 yet.
Trial pages with the registry record and the public commentary we have indexed so far. The report is built on order from the trial page. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| Breast cancer · 8 | |||||||
| SATEEN sacituzumab govitecan plus trastuzumab placed at ESMO Breast Cancer 2026 by 6 sources NCT06100874 · Adrienne G. Waks DeepView → | HER2+ metastatic breast cancer after trastuzumab deruxtecan | Phase 2 | Deep | View | |||
| CAPItello-291 capivasertib plus fulvestrant placed at ESMO Breast Cancer 2026 by 5 sources NCT04305496 · AstraZeneca DeepView → | HR+/HER2- locally advanced or metastatic breast cancer | Phase 3 | Deep | View | |||
| DESTINY-Breast11 trastuzumab deruxtecan plus paclitaxel plus trastuzumab plus pertuzumab; trastuzumab deruxtecan placed at ESMO Breast Cancer 2026 by 5 sources NCT05113251 · AstraZeneca DeepView → | high-risk HER2-positive early-stage breast cancer | Phase 3 | Deep | View | |||
| TROPION-Breast02 datopotamab deruxtecan placed at ESMO Breast Cancer 2026 by 4 sources NCT05374512 · AstraZeneca DeepView → | first-line inoperable or metastatic triple-negative breast cancer | Phase 3 | Deep | View | |||
| PHERGain trastuzumab plus pertuzumab placed at ESMO Breast Cancer 2026 by 3 sources NCT03161353 · MedSIR DeepView → | HER2-positive early breast cancer | Phase 2 | Deep | View | |||
| PREcoopERA giredestrant; giredestrant plus triptorelin placed at ESMO Breast Cancer 2026 by 3 sources NCT05896566 · ETOP IBCSG Partners Foundation DeepView → | premenopausal ER-positive/HER2-negative early breast cancer | Phase 2 | Deep | View | |||
| VERITAC-2 vepdegestrant (ARV-471) placed at ESMO Breast Cancer 2026 by 3 sources NCT05654623 · Pfizer DeepView → | ER-positive/HER2-negative advanced breast cancer | Phase 3 | Deep | View | |||
| SERENA-6 camizestrant plus palbociclib; camizestrant plus abemaciclib; camizestrant plus ribociclib placed at ESMO Breast Cancer 2026 by 2 sources NCT04964934 · AstraZeneca DeepView → | ESR1-mutated ER-positive HER2-negative metastatic breast cancer | Phase 3 | Deep | View | |||
| HER2-negative breast cancer · 1 | |||||||
| TRAK-ER palbociclib plus fulvestrant placed at ESMO Breast Cancer 2026 by 2 sources NCT04985266 · Royal Marsden NHS Foundation Trust StandardView → | ER-positive HER2-negative breast cancer with molecular relapse | Phase 2 | Standard | View | |||